Samsara BioCapital’s Atreca, Inc. Class A Common Stock BCEL Stock Holding History

Samsara BioCapital’s Portfolio BCEL Stock Details BCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-262,827	Closed	-$300K	–	56
2023 Q1	$300K	Sell	262,827 -134,008	-34%	-$195K	0.06%	46
2022 Q4	$318K	Hold	396,835	–	–	0.07%	48
2022 Q3	$623K	Hold	396,835	–	–	0.15%	46
2022 Q2	$710K	Hold	396,835	–	–	0.19%	47
2022 Q1	$1.26M	Hold	396,835	–	–	0.32%	43
2021 Q4	$1.2M	Hold	396,835	–	–	0.23%	41
2021 Q3	$2.47M	Hold	396,835	–	–	0.39%	36
2021 Q2	$3.38M	Hold	396,835	–	–	0.42%	35
2021 Q1	$6.08M	Sell	396,835 -78,108	-16%	-$1.27M	1.12%	21
2020 Q4	$7.67M	Sell	474,943 -142,617	-23%	-$2.14M	0.77%	15
2020 Q3	$8.63M	Buy	617,560 +107,264	+21%	+$1.6M	2.41%	12
2020 Q2	$10.9M	Sell	510,296 -86,542	-15%	-$1.53M	3.49%	10
2020 Q1	$9.88M	Buy	596,838 +5,470	+0.9%	+$99.2K	5.68%	7
2019 Q4	$9.15M	Hold	591,368	–	–	4.38%	8
2019 Q3	$7.24M	Hold	591,368	–	–	4.93%	8
2019 Q2	$11.1M	Buy	+591,368	New	+$10.7M	7.36%	7

Other funds holding BCEL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $15.5B AUM 38.81% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Samsara BioCapital's BCEL Position: Q2 2023 in Review

Samsara BioCapital sold out of Atreca, Inc. Class A Common Stock (BCEL) in Q2 2023, closing a stake of 262,827 shares — an estimated $300K sold.

Samsara BioCapital first reported a position in BCEL in Q2 2019 and held it in 16 quarters. The position peaked at $11.1M in Q2 2019. 53 funds tracked by Wall St. Rank hold BCEL as of Q2 2023.

Samsara BioCapital reported no remaining Atreca, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
Samsara BioCapital sold 262,827 Atreca, Inc. Class A Common Stock shares in Q2 2023, an estimated $300K.
Samsara BioCapital first reported a position in Atreca, Inc. Class A Common Stock in Q2 2019 and held it in 16 quarters.
Samsara BioCapital's Atreca, Inc. Class A Common Stock position peaked at $11.1M in Q2 2019.
53 funds tracked by Wall St. Rank held Atreca, Inc. Class A Common Stock as of Q2 2023.

Based on Samsara BioCapital's 13F filing for Q2 2023, filed 14 Aug 2023.